首页> 外国专利> New 6-acylamino-4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors or respiratory or gastrointestinal diseases

New 6-acylamino-4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors or respiratory or gastrointestinal diseases

机译:新的6-酰基氨基-4-氨基喹唑啉或喹啉衍生物是酪氨酸激酶介导的信号转导抑制剂,例如可用于药物治疗。用于治疗肿瘤或呼吸道或胃肠道疾病

摘要

6-Acylamino-4-amino-quinazoline or quinoline derivatives (I) are new. 6-Acylamino-4-amino-quinazoline or quinoline derivatives of formula (I) and their tautomers, stereoisomers and salts are new. X = C(CN) or N; Ra, Rc = H or T; T = 1-4C alkyl; Rb = Ph', CH2Ph' or CHMePh'; Ph' = phenyl substituted by R1-R3; R1, R2 = H, halo, T, OH, OT, 3-6C cycloalkyl, 4-6C cycloalkoxy, 2-5C alkenyl, 2-5C alkynyl, Ar, OAr, CH2Ar or OCH2Ar; 3-5C alkenyloxy or 3-5C alkynyloxy (both not alpha -unsaturated), S(O)nT or S(O)nCF3, Me or OMe substituted by 1-3 F, Et or OEt substituted by 1-5 F, or CN, NH2, NHT or N(T)2; or R1+R2 = CH=CHCH=CH, CH=CHNH or CH=NNH bonded to adjacent C; n = 0-2; R3 = H, F, Cl, Br, T, CF3 or OCF3; Rd = H, 1-6C alkoxy, 4-7C cycloalkoxy or (3-7C) cycloalkyl-V-O-, 2-6C alkoxy substituted (but not in the 1-position) by OH, OT, 4-7C cycloalkoxy, (3-7C) cycloalkyl-V-O-, N(T)2, pyrrolidino, piperidino, morpholino, piperazino or N-(T)-piperazino (the cyclic imino groups being optionally substituted (os) by 1 or 2 U), or tetrahydrofuran-3-yloxy, tetrahydropyran-(3- or 4-)yloxy, tetrahydrofuranylmethoxy or tetrahydropyranylmethoxy; U = Me or Et; V = 1-4C alkylene; A = vinylene, vinylidene or 1,3-butadien-1,4-ylene (all os by 1 or 2 CF3 or 1 or 2 Me), or ethynylene; B' = 1-6C alkylene (os by 1 or 2 F), or can also be a direct bond if C' is bonded via C; C' = (i) 2,2-(D)-pyrrolidino, 3,3-(E)-pyrrolidino, 2,2-(D)-piperidino, 2,2-(D)-hexahydroazepino, 3,3- or 4,4-(E)-piperidino, 3,3- or 4,4-(E)-hexahydroazepino or 2,2- or 3,3-(D)-piperazino (os by T in the 4-position); (ii) pyrrolidino or piperidino, having two vicinal C bridged by OCOCH2, CH2OCO, OCO(CH2)2, CH2OCOCH2, (CH2)2OCO, OCOCH2N(R4) or OCOCH2O (all os by 1-2 U), provided that the heteroatom is not bonded to the 2- or 5-position of pyrrolidine or the 2- or 6-position of piperidine; (iii) piperazino or 4-(T)-piperazino, having the 2- and 3-positions bridged by CH2OCOCH2 or (CH2)2OCO (both os by 1 or 2 U); (iv) piperazino having the 3- and 4-positions bridged by COO(CH2)2 or CH2OCOCH2 or (CH2)2OCO (both os by 1 or 2 U), the left-hand end of which is bonded in the 3-position; (v) pyrrolidino, piperidino, hexahydroazepino, 4-(T)-piperazino or 4-(T)-homopiperazino, all C-substituted by R5; (vi) 3-(R'5)-pyrrolidino, 3- or 4-(R'5)-piperidino or 3- or 4-(R'5)-hexahydroazepino; (vii) 4-(R6)-piperazino or 4-(R6)-homopiperazino; (viii) 3-(R'6)-pyrrolidino, 3- or 4-(R'6)-piperidino or 3- or 4-(R'6)-hexahydroazepino; (ix) pyrrolidino, piperidino, hexahydroazepino, 4-(T)-piperazino or 4-(T)-homopiperazino, all substituted by R5-V-, R'6-V- or R4N(R6)CO; (x) pyrrolidino 3-substituted by R5CONR4, R5-V-CONR4, R'6-V-CONR4, R'5-V-CONR4, R5-V-Y- or Y'-Y-; (xi) piperidino or hexahydroazepino, both 3- or 4-substituted by R5CONR4, R5-V-CONR4, R'6-V-CONR4, R'5-V-CONR4, R5-V-Y- or Y'-Y-; (xii) piperazino or homopiperazino, both 4-substituted by R5-V-, R5-V-CO-, R'6-V-CO- or Y'; (xiii) pyrrolidino, piperidino, hexahydroazepino, 4-(T)-piperazino or 4-(T)-homopiperazino, all C-substituted by R'5; (xiv) 3-(Y''-Y-)-pyrrolidino, 3- or 4-(Y''-Y-)-piperidino or 3-or 4-(Y''-Y-)-hexahydroazepino; (xiv) piperazino or homopiperazino, both 4-substituted by R'5-V-CO- or Y''; (xv) pyrrolidinyl or piperidinyl, both 1-substituted by R5-V-, R5-CO-, R'6-V-CO or R'5-VCO-, or by 2-4C alkyl substituted (but not in the 1-position) by R'5 or R'6; (xvi) pyrrolidin-3-yl-N(R4)- or piperidin-(3- or 4-)-yl-N(R4)-, both substituted on the ring N by R5-V-, R5-CO-, R'6-V-CO- or R'5-V-CO-, or by 2-4C alkyl substituted (but not in the 1-position) by R'5 or R'6; (xvii) R5-V-N(R4)-; or (xviii) 2-4C alkyl-N(R4)-, where alkyl is substituted (but not in the 1-position) by R'5 or R'6; D = CH2OCOCH2, (CH2)2OCO, CH2OCO(CH2)2, (CH2)2OCOCH2 or (CH2)3OCO (all os by 1 or 2 U); E = OCO(CH2)2, CH2OCOCH2, (CH2)2OCO, OCO(CH2)3, CH2OCO(CH2)2, (CH2)2OCOCH2, (CH2)3OCO, OCOCH2N(R4)CH2, CH2OCOCH2N(R4), OCOCH2OCH2 or CH2OCOCH2O (all os by 1-2 U); R4 = H or T; R5 = 2-oxo-tetrahydrofuranyl, 2-oxo-tetrahydropyranyl, 2-oxo-1,4-dioxanyl or 2-oxo-4-(T)-morpholinyl; R'5 = 2-oxo-morpholino (os by 1-2 U); R6 = 2-oxo-tetrahydrofuran-(3- or 4)-yl or 2-oxo-tetrahydropyran-(3-, 4- or 5)-yl (both os by 1-2 U); R'6 = NR4R6, OR6 or S(O)nR6; V = 1-4C alkylene; Y = O, S(O)n, NH or NT; Y' = 2-4C alkyl os (but not in the 1-position) by R'6; Y'' = 2-4C alkyl substituted (but not in the 1-position) by R'6; Ar = phenyl os by 1 or 2 R'; R' = halo, U, CF3 or OU; or (R')2 on adjacent C = 3-4C alkylene, OCH2O or CH=CHCH=CH. An Independent claim is also included for the preparation of (I).
机译:6-酰基氨基-4-氨基喹唑啉或喹啉衍生物(I)是新的。式(I)的6-酰基氨基-4-氨基喹唑啉或喹啉衍生物及其互变异构体,立体异构体和盐是新的。 X = C(CN)或N; Ra,Rc = H或T; T = 1-4C烷基; Rb = Ph',CH2Ph'或CHMePh'; Ph'=被R1-R3取代的苯基; R1,R2 = H,卤素,T,OH,OT,3-6C环烷基,4-6C环烷氧基,2-5C烯基,2-5C炔基,Ar,OAr,CH2Ar或OCH2Ar; 3-5C烯氧基或3-5C炔氧基(都不是不饱和的α),S(O)nT或S(O)nCF3,Me或OMe被1-3 F取代,Et或OEt被1-5 F取代或CN,NH2,NHT或N(T)2;或R 1 + R 2 =与相邻的C键合的CH = CHCH = CH,CH = CHNH或CH = NNH; n = 0-2; R3 = H,F,Cl,Br,T,CF3或OCF3; Rd = H,1-6C烷氧基,4-7C环烷氧基或(3-7C)环烷基-VO-,2-6C烷氧基被OH,OT,4-7C环烷氧基取代(但不在1位) -7C)环烷基-VO-,N(T)2,吡咯烷基,哌啶子基,吗啉代,哌嗪子基或N-(T)-哌嗪子基(环状亚氨基任选被1或2 U取代(os))或四氢呋喃- 3-基氧基,四氢吡喃-(3-或4-)基氧基,四氢呋喃基甲氧基或四氢吡喃基甲氧基; U =我或Et; V = 1-4C亚烷基; A =亚乙烯基,亚乙烯基或1,3-丁二烯-1,4-亚乙基(所有os为1或2 CF 3或1或2Me)或亚乙炔基; B′= 1-6C亚烷基(在1或2F上的os),或者如果C′通过C键合也可以是直接键; C′=(i)2,2-(D)-吡咯烷基,3,3-(E)-吡咯烷基,2,2-(D)-哌啶子基,2,2-(D)-六氢阿斯匹丁基,3,3-或4,4-(E)-哌啶子基,3,3-或4,4-(E)-六氢阿斯匹蒂诺或2,2-或3,3-(D)-哌嗪子基(在4位为T的os) ; (ii)吡咯烷基或哌啶子基,具有两个邻位碳,分别通过OCOCH2,CH2OCO,OCO(CH2)2,CH2OCOCH2,(CH2)2OCO,OCOCH2N(R4)或OCOCH2O(均由1-2 U取代)桥接不与吡咯烷的2或5位或哌啶的2或6位键合; (iii)哌嗪子基或4-(T)-哌嗪子基,其2-和3-位被CH 2 OCOCH 2或(CH 2)2 OCO(两者均为1或2 U)桥接; (iv)3位和4位被COO(CH2)2或CH2OCOCH2或(CH2)2OCO(两者均为1或2 U)桥接的piperazino,其左端键合在3位; (v)吡咯烷基,哌啶子基,六氢氮杂环庚烷,4-(T)-哌嗪子基或4-(T)-均哌嗪子基,均被R5 C-取代; (vi)3-(R'5)-吡咯烷基,3-或4-(R'5)-哌啶子基或3-或4-(R'5)-六氢阿斯匹蒂诺; (vii)4-(R6)-哌嗪子或4-(R6)-均哌嗪子; (viii)3-(R'6)-吡咯烷基,3-或4-(R'6)-哌啶子基或3-或4-(R'6)-六氢阿斯皮蒂诺; (ix)吡咯烷基,哌啶子基,六氢氮杂环庚烷,4-(T)-哌嗪子基或4-(T)-均哌嗪子基,均被R5-V-,R'6-V-或R4N(R6)CO取代; (x)被R5CONR4,R5-V-CONR4,R'6-V-CONR4,R'5-V-CONR4,R5-V-Y-或Y'-Y- 3取代的吡咯烷基; (xi)被R5CONR4,R5-V-CONR4,R'6-V-CONR4,R'5-V-CONR4,R5-V-Y-或Y'-Y- 3-或4-取代的哌啶子基或六氢氮杂环庚烷; (xii)哌嗪子基或高哌嗪子基,均被R5-V-,R5-V-CO-,R'6-V-CO-或Y'4-取代; (xiii)吡咯烷基,哌啶子基,六氢氮杂环庚烷,4-(T)-哌嗪子基或4-(T)-均哌嗪子基,全部被R'5 C取代; (xiv)3-(Y''-Y-)-吡咯烷酮,3-或4-(Y''-Y-)-哌啶子基或3-或4-(Y''-Y-)-六氢阿哌替尼; (xiv)都被R'5-V-CO-或Y''4取代的哌嗪子基或高哌嗪子基; (xv)吡咯烷基或哌啶基,均被R5-V-,R5-CO-,R'6-V-CO或R'5-VCO-或被2-4C烷基取代(但不在1 -位置)的R'5或R'6; (xvi)吡咯烷-3-基-N(R4)-或哌啶-(3-或4-)-基-N(R4)-,两者在环N上均被R5-V-,R5-CO-取代, R'6-V-CO-或R'5-V-CO-,或被R'5或R'6取代(但不在1位)的2-4C烷基; (xvii)R5-V-N(R4)-; (xviii)2-4C烷基-N(R4)-,其中烷基被R'5或R'6取代(但不在1-位); D = CH 2 OCOCH 2,(CH 2)2 OCO,CH 2 OCO(CH 2)2,(CH 2)2 OCOCH 2或(CH 2)3 OCO(所有os为1或2U); E = OCO(CH2)2,CH2OCOCH2,(CH2)2OCO,OCO(CH2)3,CH2OCO(CH2)2,(CH2)2OCOCH2,(CH2)3OCO,OCOCH2N(R4)CH2,CH2OCOCH2N(R4),OCOCH2OCH2或CH2OCOCH2O(所有操作系统为1-2 U); R4 = H或T; R5 = 2-氧代-四氢呋喃基,2-氧代-四氢吡喃基,2-氧代-1,4-二氧杂烷基或2-氧代-4-(T)-吗啉基; R'5 = 2-氧代吗啉代(os by 1-2 U); R6 = 2-氧代-四氢呋喃-(3-或4)-基或2-氧代-四氢吡喃-(3-,4-或5)-基(两者均为1-2U); R'6 = NR4R6,OR6或S(O)nR6; V = 1-4C亚烷基; Y = O,S(O)n,NH或NT; Y′= R′6的2-4C烷基os(但不在1-位); Y” =被R'6取代(但不在1-位)的2-4C烷基; Ar = 1或2 R'的苯基os; R'=卤素,U,CF3或OU;或在相邻的C = 3-4C亚烷基,OCH 2 O或CH = CHCH = CH上的(R′)2。独立索赔也包括在准备(I)中。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号